Survival and prognostic factors in pediatric patients with medulloblastoma treated at a national pediatric hospital in Peru: a retrospective cohort
Search for other papers by Jose D. Flores-Sanchez in
jns
Google Scholar
PubMed
Search for other papers by Daniela A. Perez-Chadid in
jns
Google Scholar
PubMed
Search for other papers by Rosdali Y. Diaz-Coronado in
jns
Google Scholar
PubMed
Search for other papers by Eddy Hernandez-Broncano in
jns
Google Scholar
PubMed
Search for other papers by Carlos F. Ugas-Charcape in
jns
Google Scholar
PubMed
Search for other papers by Alberto Ramirez in
jns
Google Scholar
PubMed
Search for other papers by Augusto E. Racchumí-Vela in
jns
Google Scholar
PubMed
Search for other papers by Frederick A. Boop in
jns
Google Scholar
PubMed
Search for other papers by Ivethe Preguntegui in
jns
Google Scholar
PubMed
OBJECTIVE
The objectives of this study were to determine the overall survival (OS) and event-free survival (EFS) rates of patients with medulloblastoma treated in a national pediatric hospital in Peru, as well as to identify demographic, clinical, imaging, postoperative, and histopathological characteristics and prognostic factors associated with OS and EFS.
开云体育世界杯赔率
The authors conducted a retrospective study analyzing information from the medical records of children with a diagnosis of medulloblastoma who underwent surgical treatment at the Instituto Nacional de Salud del Niño—San Borja, a public hospital in Lima, Peru, from 2015 to 2020. Clinical-epidemiological variables, degree of disease extension, risk stratification, extent of resection, postoperative complications, status of oncological treatment received, histological subtype, and neurological sequelae were taken into account. The Kaplan-Meier method and Cox regression analysis were used to estimate OS, EFS, and prognostic factors.
RESULTS
Of the 57 children evaluated with complete medical records, only 22 children (38.6%) underwent complete oncological treatment. OS was 37% (95% CI 0.25–0.55) at 48 months. EFS was 44% (95% CI 0.31–0.61) at 23 months. High-risk stratification—meaning patients with ≥ 1.5 cm2of residual postoperative tumor, those younger than 3 years, those with disseminated disease (HR 9.69, 95% CI 1.40–67.0, p = 0.02), and those who underwent subtotal resection (HR 3.78, 95% CI 1.09–13.2, p = 0.04)—was negatively associated with OS. Failure to receive complete oncological treatment was negatively associated with OS (HR 20.0, 95% CI 4.84–82.6, p < 0.001) and EFS (HR 7.82, 95% CI 2.47–24.7, p < 0.001).
CONCLUSIONS
操作系统和EFS medullob患者lastoma in the author’s milieu are below those reported in developed countries. Incomplete treatment and treatment abandonment in the authors’ cohort were also high compared with high-income country statistics. Failure to complete oncological treatment was the most important factor associated with poor prognosis, both in terms of OS and EFS. High-risk patients and subtotal resection were negatively associated with OS. Interventions are needed to promote the completion of adjuvant oncological therapy for medulloblastoma in the disadvantaged Peruvian population.
ABBREVIATIONS
CNS = central nervous system ; EFS = event-free survival ; LMIC = low- and middle-income country ; OS = overall survival ; PAHO = Pan-American Health Organization .
开云体育平台上